Patent Extends Protection for its Novel Compounds and Methods Already granted in Australia and Japan

“As an innovative pharmaceutical company, our IP portfolio is one of our greatest and most important assets. Obtaining a U.S. patent for our core technology constitutes a major achievement for us, especially as we are one of the few companies in the field that has IP protection on compounds and not only indications. We are pleased that the U.S. Patent and Trademark Office has again recognized the uniqueness of our compounds and methodologies and granted this patent,” said Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc.

This patent further strengthens the Company’s intellectual property portfolio and protection of its core technologies, and in one of the most important markets in the world.

This is SciSparc’s fourth granted patent in the U.S. Recently, the Company announced it has been granted the same patent in Australia and Japan.

Dr. Zuloff-Shani added, “Our growing portfolio of patents is a testament to the dedication and innovation of the SciSparc team and strengthens our commitment to continue the work we do to bring therapies to patients suffering with the challenges associated with disorders of the central nervous system, for whom there is currently no effective treatment.”

About SciSparc (NASDAQ:SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome and for the treatment of obstructive sleep apnea; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. For example, SciSparc is using forward-looking statements when it discusses its potential to bring therapies to patients suffering with the challenges associated with disorders of the central nervous system. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 30, 2021, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
[email protected]
Tel: +972-3-6167055

TEL AVIV, Israel, Sept. 7, 2021 /PRNewswire/ — SciSparc Ltd. (OTC Pink: SPRCF), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company”), today announced it has been awarded two patents from the Australian Patent Office and one from the Japanese Patent Office concerning the proprietary compounds and methods underlying the Company’s core technologies (the “Patents”), as listed below:

Australian Patent #AU2016254685A1 and Japanese Patent #2018-507796

Pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.

Australian Patent #AU2016263292A1

Pharmaceutical compositions comprising opioids and N-acylethanolamines, and methods for their use in preventing and treating a variety of opioid- responsive conditions and opioid-related side-effects.

Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented on the announcement, “I am pleased that the Australian and Japanese patent offices have recognized the uniqueness of our pharmaceutical compounds. This is important for the long-term value of any associated products as the Patents establish claims that safeguard the core technologies at the heart of our product pipeline.”

“The approvals strengthen the value of our IP portfolio and build on our competitive advantage in the emerging psycho-pharma market. We filed the International PCT applications to facilitate our ability to participate in the global market. Australia and Japan are the first countries to grant the Patents and I expect Europe, Israel, Canada and China to follow,” Zuloff-Shani concluded.

About SciSparc (OTC Pink:SPRCF):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses expectations regarding the long-term value of SciSparc products and the potential for future patents. The transaction described here may never be consummated and definitive agreement(s) may not be executed, and, if executed, such agreement(s) may be subject to conditions before it can be completed. In addition, the market for products contemplated by the letter of intent is in a period of regulatory and business uncertainty and financial and business results from such businesses are uncertain. Historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the SEC on March 30, 2021, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
[email protected]
Tel: +972-3-6167055

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

TACOMA, WA / ACCESSWIRE / May 17, 2021 / IONIC BRANDS CORP. (CSE:IONC)(OTC PINK:IONKF)(FRA:1B3) (“IONIC BRANDS” or the “Company”) is a regional manufacturer of innovative cannabis consumables and concentrate extract products, is pleased to announce that together with REPS JAPAN Co. Ltd., (“REPS”), the parties have executed a License Agreement that will allow REPS the exclusive rights to produce, manufacture, and distribute CBD vape products throughout Japan under the IONIC brand name.

The companies have been preparing to launch IONIC branded cannabidiol (“CBD”) products in Japan since early 2018. After three years of strategic planning, market research, streamlining importation, formulation research and development, and identification of reliable distribution channels, IONIC BRANDS and REPS are now ready to begin selling in Japan.

In the coming weeks of May 2021, the two companies have planned to launch a CBD version of the American IONIC Black Line Disposable Vape Pen for test marketing. The vape oil used is 40% hemp stem-derived CBD and enhanced with various terpenes found in hemp and other plants. Products will be distributed within offline shops throughout Okinawa, Tokyo and online nationwide through one of the largest CBD e-commerce site, http://cbd-library.com, and a direct-to-consumer site. The companies plan to use crowd testing platforms, which are popular in Japan, to test new flavors and devices for this young and growing CBD market.

Dr. Zachary Bell, IONIC BRANDS Chief Science Officer and founder of REPS, has been with the Company since 2017 and lives in Okinawa, Japan. Dr. Bell founded REPS as his own private research company that focuses on developing IONIC BRANDS’ R&D programs for both the U.S. and emerging Asian markets. REPS is located at the Okinawa Institute of Science and Technology (OIST), one of Japan’s premier graduate universities and research institutes.

Unlike the US, the CBD market in Japan has not been saturated with many brands and types of products. While smoking tobacco is still quite popular in Japan, safer alternatives are a growing trend with more and more consumers adopting electronic vaporizers. Education on using CBD vapes are still in progress for this new market, but IONIC is seeing a growing consumer interest in CBD products and vapes. In addition to offering the natural hemp and cannabis flavored vape oils IONIC is known for, REPS is developing flavor options using provincial aromas and tastes.

IONIC BRANDS Chairman and CEO John P. Gorst commented, “IONIC BRANDS and Dr. Bell have been collaborating for several months on the development of a world-class, premium CBD blend that is sourced locally in Japan and working within laboratories of the Okinawa Institute of Science and Technology. We will be jointly selling our products online with REPS direct-to-consumer, as well as select retail locations in Tokyo and Okinawa Japan. This will represent IONIC BRANDS’ first international licensing agreement outside of the United States”.

Dr. Bell, was quoted saying, “While working in the US at IONIC BRANDS, I recognized we would be a more valuable company if we had stronger relationships with academic and biomedical researchers as a means of driving internal innovation and technology development. IONIC BRANDS, and my science team at REPS, are excited to see our years of hard work in Japan finally pay off. Furthermore, IONIC is the perfect fit for Japanese market. Japan is a country that has a high attention to detail and strives to achieve perfection, thus a well suited for IONIC. We are confident the premium luxury IONIC devices, packaging, and formulas will be fast moving products in Japan. Being able to have IONIC products “Made-In-Japan” is one of my biggest contributions to IONIC BRANDS to-date during my 4 years with the Company.”

About IONIC BRANDS Corp.

The Company is dedicated to building a regionally based multi-state consumer packaged goods company with a highly respected cannabis concentrate brand portfolio with strong roots in the premium and luxury segments of vape, concentrates and consumables. The cornerstone Brand of the portfolio, IONIC, is a top concentrates brand in Washington State along with its economy brand Dabulous and has aggressively expanded throughout the Pacific Northwest of the United States. The brand is currently operating in Washington and Oregon. IONIC BRANDS’ strategy is to be the leader of the highest-value segments of the cannabis market.

On behalf of IONIC BRANDS CORP.

John Gorst
Chairman & Chief Executive Officer

For more information visit www.ionicbrands.com or contact:

John Gorst
[email protected]
+1.253.248.7927

To stay better informed with the current events of the company you can join our investor community at https://www.ionicbrands.com/investor-community

All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The risks are without limitations the price for cannabis and related products will remain consistent and the consumer demand remains strong; availability of financing to the Company to develop the retail locations; retention of key employees and management; changes in State and/or municipal regulations of retail operations and changes in government regulations generally. Important factors that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission and the Alberta Securities Commission.

SOURCE: IONIC Brands Corp.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.